TorreyPines Therapeutics Initiates Phase II Study Of Muscarinic Agonist NGX267 For Treatment Of Xerostomia

TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren’s syndrome. The company is conducting a randomized, double-blind, placebo-controlled, cross-over study with a Latin square design to evaluate the safety, tolerability and efficacy of this once-a-day compound.

More: continued here

Comments are closed.



Pay Less for Generic - : Pay Less for Generic
Pills Store Online - Buy Drugs: Pills sotre online
Reliable Prescriptions Online - : Reliable Prescriptions Online
Rx Pills for You - : Rx Pills for You
RX Pill Vault - Buy Drugs: Interested in buying Rx pills? Here is the link for you.
Buy Cool RX - Order Pharmacy Drugs Online: Order Cool Pharmacy Drugs Online.
Drug any time - : Drug any time
My super dtrug store - : My super dtrug store
Latest News...